Beaconlight Capital LLC bought a new position in Humana Inc. (NYSE:HUM - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm bought 8,220 shares of the insurance provider's stock, valued at approximately $3,265,000. Humana comprises approximately 1.2% of Beaconlight Capital LLC's portfolio, making the stock its 21st biggest position.
Other institutional investors have also modified their holdings of the company. Montag A & Associates Inc. increased its position in Humana by 1,880.0% during the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider's stock worth $25,000 after purchasing an additional 94 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Humana in the 2nd quarter valued at approximately $26,000. Fideuram Asset Management Ireland dac purchased a new stake in shares of Humana in the 4th quarter valued at approximately $27,000. Trust Co. of Vermont acquired a new stake in shares of Humana during the 2nd quarter worth approximately $28,000. Finally, Reflection Asset Management purchased a new stake in shares of Humana during the 4th quarter valued at approximately $29,000. Hedge funds and other institutional investors own 92.38% of the company's stock.
Analysts Set New Price Targets
A number of research analysts recently commented on HUM shares. Jefferies Financial Group upgraded Humana from a "buy" rating to a "buy" rating in a report on Wednesday, May 20th. JPMorgan Chase & Co. lifted their target price on Humana from $316.00 to $393.00 and gave the company a "neutral" rating in a research report on Monday, August 10th. UBS Group started coverage on Humana in a research note on Thursday, July 30th. They issued a "buy" rating on the stock. Guggenheim increased their price target on Humana from $269.00 to $471.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. Finally, William Blair started coverage on shares of Humana in a report on Wednesday, May 20th. They issued an "outperform" rating on the stock. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $403.91.
Read Our Latest Stock Report on Humana
Humana Stock Up 0.4%
Humana stock opened at $386.92 on Monday. The company has a market capitalization of $46.46 billion, a PE ratio of 36.61, a price-to-earnings-growth ratio of 2.20 and a beta of 0.72. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.74 and a current ratio of 1.74. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $428.88. The firm has a 50 day moving average price of $385.60 and a 200 day moving average price of $289.17.
Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping analysts' consensus estimates of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%.The company had revenue of $40.89 billion for the quarter, compared to analysts' expectations of $40.58 billion. During the same period in the prior year, the firm earned $6.27 earnings per share. The firm's revenue was up 26.2% compared to the same quarter last year. Research analysts expect that Humana Inc. will post 9.12 earnings per share for the current year.
Humana Company Profile
(
Free Report)
Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
See Also
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
